{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.18","upperLimit":"22.26","value":"16.22"},{"groupId":"OG001","lowerLimit":"16.74","upperLimit":"26.51","value":"21.63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"431"}],"units":"Participants"}],"description":"PD is defined as \\>/=20% relative increase and \\>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, or appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"NUMBER","populationDescription":"ITT population: all randomized participants, whether or not the assigned study treatment was received","reportingStatus":"POSTED","timeFrame":"From Day 1 to PD or death from any cause, assessed up to 12 months","title":"Percentage of Participants Who Are Alive Without Progression Event at Month 12 Assessed Using RECIST v1.1","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}